Results: Bonesupport Holding AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts

It's been a mediocre week for Bonesupport Holding AB (publ) (STO:BONEX) shareholders, with the stock dropping 16% to kr200 in the week since its latest second-quarter results. The result was positive overall - although revenues of kr356m were in line with what the analysts predicted, Bonesupport Holding surprised by delivering a statutory profit of kr1.23 per share, modestly greater than expected. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

Taking into account the latest results, the most recent consensus for Bonesupport Holding from six analysts is for revenues of kr1.49b in 2026. If met, it would imply a solid 16% increase on its revenue over the past 12 months. In the lead-up to this report, the analysts had been modelling revenues of kr1.50b and earnings per share (EPS) of kr4.63 in 2026. So we can see that while the consensus made no real change to its revenue estimates, it also no longer provides an earnings per share estimate. This suggests that revenues are what the market is focusing on after the latest results.

Check out our latest analysis for Bonesupport Holding

There's been no real change to the consensus price target of kr361, with Bonesupport Holding seemingly executing in line with expectations. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. The most optimistic Bonesupport Holding analyst has a price target of kr415 per share, while the most pessimistic values it at kr275. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await Bonesupport Holding shareholders.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. We can infer from the latest estimates that forecasts expect a continuation of Bonesupport Holding'shistorical trends, as the 34% annualised revenue growth to the end of 2026 is roughly in line with the 37% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 13% annually. So although Bonesupport Holding is expected to maintain its revenue growth rate, it's definitely expected to grow faster than the wider industry.

The Bottom Line

The most important thing to take away is that the analysts reconfirmed their revenue estimates for next year, suggesting that the business is performing in line with expectations. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. The consensus price target held steady at kr361, with the latest estimates not enough to have an impact on their price targets.

We have estimates for Bonesupport Holding from its six analysts out to 2028, and you can see them free on our platform here.

You can also see our analysis of Bonesupport Holding's Board and CEO remuneration and experience, and whether company insiders have been buying stock.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.